Key facts
- Third-quarter net profit rose 88.92% to 2.46 billion yuan.
- Third-quarter revenue increased 20.55% to 8.95 billion yuan.
- Innovative drug sales reached 13.87 billion yuan in the first nine months, up 17.05%.
Hengrui Pharmaceuticals, a major Chinese drug maker, announced its third-quarter financial results, showing a significant increase in both revenue and net profit. The company reported revenue of 8.95 billion yuan, a 20.55% rise year-over-year, surpassing analyst expectations. Net profit surged by 88.92% to 2.46 billion yuan, exceeding the consensus estimate. These gains were attributed to stronger sales of innovative drugs and revenue from out-licensing agreements. For the first nine months of 2026, Hengrui's revenue reached 24.41 billion yuan, with net profit at 6.92 billion yuan. Innovative drug sales accounted for a substantial portion of total drug sales, with notable growth in non-oncology segments. The company also advanced its research and development pipeline, securing approvals and advancing new drug applications, particularly in the GLP-1 class. Significant partnerships were also highlighted, including a license agreement with Novo Nordisk for a dual agonist and a substantial upfront payment from Bristol Myers Squibb.